Clinical study of malignancies after renal transplantation and impact of routine screening for early detection: a single-center experience

Ishikawa, Nobuo; Tanabe, Kazunari; Tokumoto, Tadahiko; Shimmura, Hiroaki; Yagisawa, T; Goya, Nobuyuki; Nakazawa, Hayakazu; Toma, Hiroshi

doi:10.1016/s0041-1345(00)01487-1

Cited by 18 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results of a low risk of skin cancer in Asian people after heart and kidney transplantation have been reported in several studies. 21 – 24 The incidence of skin cancer in the general population is believed to be higher in Western people than in Asian people because of differences in ethnic factors and skin type. Different from Western people, Chinese people do not have an increased risk of developing skin cancer while receiving immunosuppressive treatments after solid organ transplantation.…”

Section: Discussionmentioning

confidence: 99%

Post-Transplant Malignancy in Liver Transplantation

Hsiao¹,

Lee²,

Ho³

et al. 2014

Medicine

View full text Add to dashboard Cite

We aim to determine the incidence of malignancy after liver transplantation (LT) compared to general population.The records of patients who received LTs at our center from October 1989 and November 2012 were retrospectively reviewed. The standardized incidence ratio (SIR) of cancer in the patients was compared to general population using the data from the Taiwan Cancer Registry. Survival was estimated using the Kaplan–Meier method.A total of 444 patients were included. Malignancy was found in 46 (28 de novo and 19 recurrent malignancies) patients (10.4%) with the median follow up of 4.2 ± 4.2 years. The median time of cancer occurrence after transplant was 1.2 ± 1.9 years (range, 0.2–9.1 years). Post-transplant lymphoproliferative disorder was the most frequent de novo malignancy (57.1% [16/28]). The cumulative incidence rates of all malignancies were 5.1%, 10.4%, 12.8%, 15.8%, and 15.8% at 1, 3, 5, 10, and 15 years, respectively. The cumulative incidence rates of de novo malignancies were 3.4%, 5.97%, 7.7%, 10.9%, and 10.9 % at 1, 3, 5, 10, and 15 years. Compared to general population, transplant recipients had significantly higher incidence of all de novo cancers (SIR: 3.26, 95% confidence interval [CI]: 2.17–4.72), hematologic (SIR: 58.4; 95% CI, 33.3–94.8), and bladder (SIR: 10.2, 95% CI: 1.1–36.7) cancers. The estimated mean survivals after transplantation in cancer-free, de novo cancer, and recurrent cancer patients were 17.7 ± 0.5, 11.3 ± 1.2, and 3.6 ± 0.6 years, respectively.There is a significantly increased risk of malignancies after LT in the Taiwanese population.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-Transplant Malignancy in Liver Transplantation

Hsiao¹,

Lee²,

Ho³

et al. 2014

Medicine

View full text Add to dashboard Cite

show abstract

“…A meta-analysis study, however, reported a relative risk of 2.6 for colorectal cancer in postYdeceased-donor liver transplantation patients compared with an age-matched general population (29). Primary sclerosing cholangitis is an important high-risk factor for colorectal cancer.…”

Section: Discussionmentioning

confidence: 98%

“…For example, Vera and colleagues (30) found a 5% incidence of colorectal cancers in recipients with primary sclerosing cholangitis versus 0.6% for recipients without nonprimary sclerosing cholangitis. Nicolaas and colleagues reported that overall transplant recipients (nonprimary sclerosing cholangitis) have an increased risk for colorectal cancer compared with the general population (relative risk: 1.8) (29). Thereby, they concluded that nonprimary sclerosing cholangitis transplant recipients do not need an intensified screening strategy for colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

De Novo Malignancies After Adult-to-Adult Living-Donor Liver Transplantation With a Malignancy Surveillance Program

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Surveillance and prevention of skin cancer in SOTRs should be reinforced because of its high morbidity (11). Skin cancers in SOTRs tend to behave more aggressively than in the general population with a higher tendency for early metastasis.…”

mentioning

confidence: 99%

Capecitabine for skin cancer prevention in solid organ transplant recipients

Jirakulaporn

Endrizzi

Lindgren

et al. 2010

Clinical Transplantation

View full text Add to dashboard Cite

Skin cancers are the most common malignancies in solid organ transplant recipients (SOTR). A case-observational, retrospective study was performed to determine the efficacy of low-dose capecitabine in the secondary prevention of skin cancers in SOTRs treated at a single institution. SOTRs with recurrent squamous cell carcinoma (SCC) and/or basal cell carcinoma (BCC) were given low-dose capecitabine 1 g/m(2) daily, days 1-14 of a 21-d treatment cycle. Skin surveillance was performed by dermatologists every 1-3 months. Cumulative incidence rates of SCC, BCC, and actinic keratosis (AK) before and after treatment were scored and statistically compared for each patient using a non-parametric Wilcoxon signed rank test. Fifteen patients (13 men and two women) with a median age of 57 yr (range 40-73) were treated. Incidence rates as measured by mean number of events per month declined by 0.33 for SCC, 0.04 for BCC, and 2.45 for AK (p < 0.05). The most common grade 3 and 4 toxicities included fatigue (40.0%), hand-foot syndrome (20.0%), and diarrhea (20.0%). The discontinuation rate at one yr was approximately 33.3%. We conclude that oral capecitabine significantly decreases the incidence rates of recurrent SCC, BCC, and AK in SOTRs and is associated with manageable toxicity.

show abstract

Clinical study of malignancies after renal transplantation and impact of routine screening for early detection: a single-center experience

Cited by 18 publications

References 14 publications

Post-Transplant Malignancy in Liver Transplantation

Post-Transplant Malignancy in Liver Transplantation

De Novo Malignancies After Adult-to-Adult Living-Donor Liver Transplantation With a Malignancy Surveillance Program

Capecitabine for skin cancer prevention in solid organ transplant recipients

Contact Info

Product

Resources

About